Gary Kohler, MD
Pulmonary Disease · Lake Charles, LANPI 1881603140
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,679 of the $20,823 with a category attached, or 84.9%. It is spread thinly across 41 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among pulmonary disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 916 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$3K
- Intuitive Surgical$3K
- Boehringer Ingelheim$2K
- Sanofi$862
- Regeneron Healthcare Solutions, Inc.$862
- plus $7K from 35 others
What the payments were for
- Food & beverage$17,67985%
- Education$3,14315%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,823 in reported general payments places this provider in the 90th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $320,084 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 259 | $196,011 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $115,995 |
| Dupixent PenDupilumab | 24 | $89,389 |
| Fasenra PenBenralizumab | 15 | $76,578 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $56,022 |
| Breo ElliptaFluticasone/Vilanterol | 93 | $44,848 |
| Ambrisentan | 12 | $33,992 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 62 | $32,502 |
| EliquisApixaban | 50 | $30,165 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $25,543 |
| Spiriva RespimatTiotropium Bromide | 31 | $23,726 |
| Spiriva HandihalerTiotropium Bromide | 21 | $17,660 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $13,006 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $11,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,828 | $382,360130 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $3,394 | $273,361414 claims |
| Grifols USA, LLCProlastin C | $616 | $115,99512 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $3,418 | $73,189103 claims |
| PfizerEliquis | $99 | $30,16550 claims |
| MerckDulera | $370 | $8,65120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Lake Charles
- Luke WilliamsLake Charles$16K
- Robert BroussardLake Charles$15K
- Clifford CourvilleLake Charles$15K
- Tashfeen MahmoodLake Charles$14K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.